A citation-based method for searching scientific literature

C Billerey, D Chopin, M H Aubriot-Lorton, D Ricol, S Gil Diez de Medina, B Van Rhijn, M P Bralet, M A Lefrere-Belda, J B Lahaye, C C Abbou, J Bonaventure, E S Zafrani, T van der Kwast, J P Thiery, F Radvanyi. Am J Pathol 2001
Times Cited: 344







List of co-cited articles
903 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.
D Cappellen, C De Oliveira, D Ricol, S de Medina, J Bourdin, X Sastre-Garau, D Chopin, J P Thiery, F Radvanyi. Nat Genet 1999
524
29


Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.
Silvia Hernández, Elena López-Knowles, Josep Lloreta, Manolis Kogevinas, Alex Amorós, Adonina Tardón, Alfredo Carrato, Consol Serra, Núria Malats, Francisco X Real. J Clin Oncol 2006
222
26

The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.
B W van Rhijn, I Lurkin, F Radvanyi, W J Kirkels, T H van der Kwast, E C Zwarthoff. Cancer Res 2001
231
24

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
Adel H Jebar, Carolyn D Hurst, Darren C Tomlinson, Colin Johnston, Claire F Taylor, Margaret A Knowles. Oncogene 2005
239
19


Oncogenic FGFR3 gene fusions in bladder cancer.
Sarah V Williams, Carolyn D Hurst, Margaret A Knowles. Hum Mol Genet 2013
244
18

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
Woonyoung Choi, Sima Porten, Seungchan Kim, Daniel Willis, Elizabeth R Plimack, Jean Hoffman-Censits, Beat Roth, Tiewei Cheng, Mai Tran, I-Ling Lee,[...]. Cancer Cell 2014
849
18

Epidemiology and risk factors of urothelial bladder cancer.
Maximilian Burger, James W F Catto, Guido Dalbagni, H Barton Grossman, Harry Herr, Pierre Karakiewicz, Wassim Kassouf, Lambertus A Kiemeney, Carlo La Vecchia, Shahrokh Shariat,[...]. Eur Urol 2013
960
17

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
Richard J Sylvester, Adrian P M van der Meijden, Willem Oosterlinck, J Alfred Witjes, Christian Bouffioux, Louis Denis, Donald W W Newling, Karlheinz Kurth. Eur Urol 2006
16

Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.
Guangwu Guo, Xiaojuan Sun, Chao Chen, Song Wu, Peide Huang, Zesong Li, Michael Dean, Yi Huang, Wenlong Jia, Quan Zhou,[...]. Nat Genet 2013
298
16

The FGFR3 mutation is related to favorable pT1 bladder cancer.
Bas W G van Rhijn, Theo H van der Kwast, Liyang Liu, Neil E Fleshner, Peter J Bostrom, André N Vis, Sultan S Alkhateeb, Chris H Bangma, Michael A S Jewett, Ellen C Zwarthoff,[...]. J Urol 2012
61
24

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology.
Jeffrey S Damrauer, Katherine A Hoadley, David D Chism, Cheng Fan, Christopher J Tiganelli, Sara E Wobker, Jen Jen Yeh, Matthew I Milowsky, Gopa Iyer, Joel S Parker,[...]. Proc Natl Acad Sci U S A 2014
460
15

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Yves Allory, Willemien Beukers, Ana Sagrera, Marta Flández, Miriam Marqués, Mirari Márquez, Kirstin A van der Keur, Lars Dyrskjot, Irene Lurkin, Marcel Vermeij,[...]. Eur Urol 2014
156
15

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.
A Gordon Robertson, Jaegil Kim, Hikmat Al-Ahmadie, Joaquim Bellmunt, Guangwu Guo, Andrew D Cherniack, Toshinori Hinoue, Peter W Laird, Katherine A Hoadley, Rehan Akbani,[...]. Cell 2017
768
15

A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.
Johanna M M van Oers, Irene Lurkin, Antonius J A van Exsel, Yvette Nijsen, Bas W G van Rhijn, Madelon N M van der Aa, Ellen C Zwarthoff. Clin Cancer Res 2005
124
14

Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.
Fiona M Platt, Carolyn D Hurst, Claire F Taylor, Walter M Gregory, Patricia Harnden, Margaret A Knowles. Clin Cancer Res 2009
178
14

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
Lucie C Kompier, Irene Lurkin, Madelon N M van der Aa, Bas W G van Rhijn, Theo H van der Kwast, Ellen C Zwarthoff. PLoS One 2010
201
14

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Elena López-Knowles, Silvia Hernández, Núria Malats, Manolis Kogevinas, Josep Lloreta, Alfredo Carrato, Adonina Tardón, Consol Serra, Francisco X Real. Cancer Res 2006
150
14

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Yohann Loriot, Andrea Necchi, Se Hoon Park, Jesus Garcia-Donas, Robert Huddart, Earle Burgess, Mark Fleming, Arash Rezazadeh, Begoña Mellado, Sergey Varlamov,[...]. N Engl J Med 2019
296
14

Frequent FGFR3 mutations in urothelial papilloma.
Bas W G van Rhijn, Rodolfo Montironi, Ellen C Zwarthoff, Adriaan C Jöbsis, Theo H van der Kwast. J Pathol 2002
122
13

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
Bas W G van Rhijn, André N Vis, Theo H van der Kwast, Wim J Kirkels, François Radvanyi, Engelbert C M Ooms, Dominique K Chopin, Egbert R Boevé, Adriaan C Jöbsis, Ellen C Zwarthoff. J Clin Oncol 2003
227
13

Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
Tahlita C M Zuiverloon, Madelon N M van der Aa, Theo H van der Kwast, Ewout W Steyerberg, Hester F Lingsma, Chris H Bangma, Ellen C Zwarthoff. Clin Cancer Res 2010
79
16

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder.
Yaoting Gui, Guangwu Guo, Yi Huang, Xueda Hu, Aifa Tang, Shengjie Gao, Renhua Wu, Chao Chen, Xianxin Li, Liang Zhou,[...]. Nat Genet 2011
495
12

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, Michiel S van der Heijden, Arjun V Balar, Andrea Necchi, Nancy Dawson, Peter H O'Donnell, Ani Balmanoukian, Yohann Loriot,[...]. Lancet 2016
12

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Eugene J Pietzak, Aditya Bagrodia, Eugene K Cha, Esther N Drill, Gopa Iyer, Sumit Isharwal, Irina Ostrovnaya, Priscilla Baez, Qiang Li, Michael F Berger,[...]. Eur Urol 2017
136
12

Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
Maximilian Burger, Madelon N M van der Aa, Johanna M M van Oers, Anke Brinkmann, Theodorus H van der Kwast, Ewout C Steyerberg, Robert Stoehr, Wim J Kirkels, Stefan Denzinger, Peter J Wild,[...]. Eur Urol 2008
116
11


Transforming fusions of FGFR and TACC genes in human glioblastoma.
Devendra Singh, Joseph Minhow Chan, Pietro Zoppoli, Francesco Niola, Ryan Sullivan, Angelica Castano, Eric Minwei Liu, Jonathan Reichel, Paola Porrati, Serena Pellegatta,[...]. Science 2012
457
11

A molecular taxonomy for urothelial carcinoma.
Gottfrid Sjödahl, Martin Lauss, Kristina Lövgren, Gunilla Chebil, Sigurdur Gudjonsson, Srinivas Veerla, Oliver Patschan, Mattias Aine, Mårten Fernö, Markus Ringnér,[...]. Clin Cancer Res 2012
425
11


Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.
Jakob Hedegaard, Philippe Lamy, Iver Nordentoft, Ferran Algaba, Søren Høyer, Benedicte Parm Ulhøi, Søren Vang, Thomas Reinert, Gregers G Hermann, Karin Mogensen,[...]. Cancer Cell 2016
266
11

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
F R Lamont, D C Tomlinson, P A Cooper, S D Shnyder, J D Chester, M A Knowles. Br J Cancer 2011
122
10

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.
Isabelle Bernard-Pierrot, Aude Brams, Claire Dunois-Lardé, Aurélie Caillault, Sixtina Gil Diez de Medina, David Cappellen, Gabriel Graff, Jean Paul Thiery, Dominique Chopin, David Ricol,[...]. Carcinogenesis 2006
99
10



Mutational heterogeneity in cancer and the search for new cancer-associated genes.
Michael S Lawrence, Petar Stojanov, Paz Polak, Gregory V Kryukov, Kristian Cibulskis, Andrey Sivachenko, Scott L Carter, Chip Stewart, Craig H Mermel, Steven A Roberts,[...]. Nature 2013
10

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
Hans von der Maase, Lisa Sengelov, James T Roberts, Sergio Ricci, Luigi Dogliotti, T Oliver, Malcolm J Moore, Annamaria Zimmermann, Michael Arning. J Clin Oncol 2005
10

Fibroblast growth factor signalling: from development to cancer.
Nicholas Turner, Richard Grose. Nat Rev Cancer 2010
10

TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.
Isaac Kinde, Enrico Munari, Sheila F Faraj, Ralph H Hruban, Mark Schoenberg, Trinity Bivalacqua, Mohamad Allaf, Simeon Springer, Yuxuan Wang, Luis A Diaz,[...]. Cancer Res 2013
164
10

Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.
Faysal A Yafi, Fadi Brimo, Jordan Steinberg, Armen G Aprikian, Simon Tanguay, Wassim Kassouf. Urol Oncol 2015
106
10

Identification of targetable FGFR gene fusions in diverse cancers.
Yi-Mi Wu, Fengyun Su, Shanker Kalyana-Sundaram, Nickolay Khazanov, Bushra Ateeq, Xuhong Cao, Robert J Lonigro, Pankaj Vats, Rui Wang, Su-Fang Lin,[...]. Cancer Discov 2013
410
9

A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges.
Erica di Martino, Darren C Tomlinson, Margaret A Knowles. Adv Urol 2012
82
10



Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.
Maria Teresa Herrera-Abreu, Alex Pearson, James Campbell, Steve D Shnyder, Margaret A Knowles, Alan Ashworth, Nicholas C Turner. Cancer Discov 2013
76
11

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.
Sandra Rebouissou, Isabelle Bernard-Pierrot, Aurélien de Reyniès, May-Linda Lepage, Clémentine Krucker, Elodie Chapeaublanc, Aurélie Hérault, Aurélie Kamoun, Aurélie Caillault, Eric Letouzé,[...]. Sci Transl Med 2014
170
9

Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.
Hikmat A Al-Ahmadie, Gopa Iyer, Manickam Janakiraman, Oscar Lin, Adriana Heguy, Satish K Tickoo, Samson W Fine, Anuradha Gopalan, Ying-bei Chen, Arjun Balar,[...]. J Pathol 2011
58
15

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.
Elizabeth A Guancial, Lillian Werner, Joaquim Bellmunt, Aristotle Bamias, Toni K Choueiri, Robert Ross, Fabio A Schutz, Rachel S Park, Robert J O'Brien, Michelle S Hirsch,[...]. Cancer Med 2014
58
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.